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Pro-opiomelanocortin (POMC) was expressed in CV-I (green monkey kidney) cells using a vaccinia virus transient ex- 
pression system [(1986) Proc. Nat]. Acad. Sci. USA 83,8122]. The system involved infection of cells with a recombinant 
vaccinia virus carrying the T7 RNA polymerase gene and transfection with a plasmid containing the mouse POMC se- 
quence flanked by the T7 RNA polymerase promoter at its S-end and the T7 RNA polymerase terminator at its 3’-end. 
Assay of the medium from transfected cells showed that l-2 fig of immunoreactive ACTH was produced/l@ cells. Anal- 
ysis of the same medium by SDS-PAGE/Western blots revealed a band of 30-36 kDa, which was immunostained with 
both ACTH and p-endorphin antisera. Labeling the transfected cells with PH]Arg, followed by immunoprecipitation and 
SDS-PAGE showed the synthesis of a major peak of POMC, 33 kDa. Purified PH]POMC expressed by CV-1 cells was 
cleaved in vitro by bovine intermediate lobe secretory vesicle pro-opiomelanocortin-converting enzyme to ACTH inter- 
mediates (19-25 kDa), B-lipotropin and p-endorphin. Thus, this work has demonstrated a technique for expressing micro- 
gram quantities of prohormones in mammalian cells, suitable for use as substrates for prohormone-converting enzymes 
in vitro. 
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1. INTRODUCTION 
Peptide hormones (e.g. insulin, vasopressin and 
ACTH) are synthesized from larger precursors 
known as prohormones [l-3]. These precursors 
are generally cleaved at pairs of basic amino acids 
and to a lesser extent at single basic residues, to 
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Part of this work has been presented at the American Society 
for Cell Biology meeting [J. Cell Biol. (1987) 105, 239a] 
yield the respective biologically active hormones 
[l-3]. The processing involves several proteolytic 
enzymes: endoproteases which cleave at paired or 
single basic residues, and exopeptidases (carbox- 
ypeptidase B-like and aminopeptidase B-like en- 
zymes) which remove basic amino acids from the 
N- and C-terminus of peptides liberated from the 
prohormone by the endoproteases. Recent studies 
have suggested that in addition to having pairs of 
basic residues as signals for processing, the confor- 
mation of the prohormone may also contribute to 
the specificity of cleavage [1,2,4]. However, little is 
known about he conformation of prohormones, 
largely due to the lack of sufficient quantities of 
these molecules necessary for X-ray diffraction 
studies. Progress in testing the ability of various 
putative processing enzymes to cleave intact pro- 
hormones has also been hindered by the 
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unavailability of radiolabeled prohormone 
substrates. Attempts have been made to produce 
large quantities of prohormones using bacterial ex- 
pression systems [5]. However, although these 
systems offer high yields, the prohormones 
generated may not be appropriately post- 
translationally modified, e.g. glycosylated. Fur- 
thermore, the prohormones are often partially 
degraded within the bacterial cell and are difficult 
to purify. 
In this communication, we report the use of a 
previously described vaccinia virus transient ex- 
pression system [6] to produce the ACTH/endor- 
phin prohormone, pro-opiomelanocortin, in CV-1 
cells, an African green monkey kidney cell line. 
This expression system overcomes the problems 
encountered in bacterial systems. We further show 
that the expressed prohormone, which was 
secreted into the medium was easily recovered in 
pure form and was processed by bovine in- 
termediate lobe secretory vesicle POMC- 
converting enzyme [7], to various hormone pro- 
ducts. This enzyme has previously been shown to 
be an aspartic protease with an acidic pH optimum 
and specific for paired basic residues of POMC 
[7-101. 
2. MATERIALS AND METHODS 
2.1. Plasmid construction 
Restriction enzymes were purchased from Bethesda Research 
Laboratories (Bethesda, MD) and New England Biolabs (Bever- 
ly, MA) and were used according to instructions provided. The 
Klenow fragment of DNA polymerase I and bacterial alkaline 
phosphatase were obtained from New England Biolabs and 
Bethesda Research Laboratories, respectively. A 946 bp cDNA 
fragment containing the entire coding region of the mouse pro- 
opiomelanocortin (POMC) was isolated from pmcPOMC (a 
generous gift from E. Herbert, Portland, OR) and inserted into 
the PAR2529 vector such that the POMC sequence was flanked 
by the T7 RNA polymerase promoter at its 5 ‘-end, and the T7 
RNA polymerase terminator at its 3’-end. The resulting 
plasmid was called pKA2. A control plasmid containing the 
POMC sequence oppositely oriented with respect o the T7 was 
called pKA5. Plasmids were prepared by centrifugation in CsCl 
and ethidium bromide as described elsewhere [1 11. 
2.2. Cells 
CV-1 (green monkey kidney) cells were grown in Dulbecco’s 
minimal essential medium (DMEM) with 10% fetal calf serum 
(FCS, purchased from Gibco, Grand Island, NY) under 10% 
COz, and used when the cells were 50-80% confluent. 
2.3. Transient expression of POMC in CV-I cells 
CV-I cells were plated at 5 x lo5 cells per 25 cm’ flask and 
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incubated overnight in 5 ml of MEM/lO% FCS. Medium was 
removed, and cells were inoculated with 1 ml of viral suspen- 
sion at a multiplicity of infection (m.0.i.) of 30 for 30 min at 
37°C with occasional rocking. The virus used was either wild 
type vaccinia or vTF7-3, a vaccinia recombinant containing the 
T7 RNA polymerase gene [6]. The viral inoculum was removed, 
cells were washed with phosphate buffered saline, and 1 ml of 
Cap04 precipitate containing 10 pg DNA (plasmid construct 
pKA2 or pKA5) was layered onto the cells. The cells were then 
incubated at room temperature for 30 min with occasional 
rocking. At 1 h post-inoculation, MEM/2.5% FCS (4 ml) was 
added and the cells were incubated at 37°C. At 5 h post- 
infection, the medium was removed, and 2 ml of MEM/2.5% 
FCS were added to the cells, and incubation continued over- 
night for 12 to 16 h at 37’C. By that time, the cells had lysed, 
and the medium was collected, centrifuged at 12000 x g for 
5 min and the supernatant analyzed for immunoreactive ACTH 
and synthesis of POMC by radioimmunoassay and Western 
blots. 
2.4. Radioimmunoassay of ACTH 
The supernatant of the medium of transfected CV-1 cells (see 
section 2.3) was radioimmunoassayed for ACTH as described 
previously [12], except that the ACTH antiserum used was DP4 
(final dilution 1: !NOOO). This antiserum binds to intact POMC 
and ACTH-related products and does not cross-react with a- 
MSH or ACTH(l-10). The primary antigenic site of the an- 
tibody is directed to the region of ACTH between residues 
1 l-39. 
2.5. Western blot identification of POMC synthesized by 
transfected CV-1 cells 
The supernatant of medium from CV-1 cells (section 2.3) was 
treated with cold 10% trichloroacetic acid (TCA) for 1 h at 
4°C. The precipitated proteins were air dried, washed 5 times 
with acetone and dried again. The precipitate was then 
resuspended in 0.125 M Tris-HCI-SDS buffer (pH 6.8) contain- 
ing 0.1% ,&mercaptoethanol and 0.002% bromophenol blue 
and electrophoresed in a 13.5% polyacrylamide slab gel (SDS- 
PAGE) using the Laemmli procedure [13]. Electroblotting and 
immunostaining procedures (Western blot) of the separated 
proteins were as described previously [12]. The antisera used for 
the Western blots were DP4 (final dilution 1: 750) for ACTH 
and DP3 (final dilution 1: 750) for ,&endorphin. The DP3 an- 
tiserum is directed towards the C-terminus of ,&endorphin and 
binds to intact POMC as well as to /3-lipotropin and @ 
endorphin. 
2.6. Radiolabeling and purification of fsHJPOMC from 
transfected CV-I cells 
CV-1 cells plated at lo6 cells175 cm’ flask were infected two 
days later with the recombinant vaccinia virus vTF7-3 and then 
transfected with the plasmid pKA2 as described in section 2.3 
with minor modifications as follows. At 5 h post-infection, 
4 ml of MEM (minus the arginine), containing 0.25% 
FCS/O.l% BSA and 3.0 mCi [‘Hlarginine (spec. act. 
59.0 Ci/mmol, DuPont-New England Nuclear, Boston, MA), 
was added to the cells. After 18-20 h incubation at 37”C, the 
medium was centrifuged and the supernatant collected as 
described above (section 2.3) and treated with cold TCA (10%) 
for 1 h at 4°C to precipitate labeled proteins. The precipitate 
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was washed with ether several times and air dried. The TCA- 
precipitated proteins were immunoprecipitated with DP4 or 
DP3 antiserum as described in [7] except hat protein A- 
Sepharose beads (Pharmacia, Piscataway, N J) were used to 
precipitate the antigen-antibody complex. The anti-ACTH im- 
munoprecipitated proteins were electrophoresed on 13.5% 
polyacrylamide-SDS (SDS-PAGE) 10 cm tube gels using the 
Laemmli procedure [13]. For the preparation f [3H]POMC as 
substrate for in vitro enzymatic cleavage, the anti-ACTH im- 
munoprecipitated proteins were electrophoretically separated 
on an acid gel (without urea) [14]. Cytochrome c was run in a 
parallel gel and the electrophoresis terminated when 
cytochrome c migrated 6.0 cm from the origin. The gel was 
sliced (1.5 mm slices) and each gel slice eluted with 1 ml of 
0.1 N HCI/0.05 mg/ml BSA. Aiiquots (5/d) ofthe eluant from 
each slice were counted for radioactivity and the fractions con- 
taining the POMC peak (Rf = 0.15 relative to cytochrome c)
were pooled and lyophilized for use as substrate. 
2.7. Incubation of expressed I~H]POMC with pro-opio- 
melanocortin-converting enzyme 
[3H]Arg-POMC (2-3 x 104 cpm) expressed, radiolabeled 
and purified as described above (section 2.6) wasincubated with 
purified bovine intermediate lobe pro-opiomelanocortin- 
converting enzyme (10-30 ng) [7] in 0.1 M sodium citrate buf- 
fer (pH 4.0) for 5 h at 37°C in a total volume of 150/zl. At the 
end of this period, aliquots of the incubate were im- 
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munoprecipitated with DP4 or DP3 antisera. The im- 
munoprecipitates were then analyzed by SDS-PAGE [13]. 
3. RESULTS 
3.1. Analysis of POMC from transfected CV-1 
cells 
Fig. 1 shows the Western blots of medium from 
CV-1 cells which were transfected under various 
condit ions. In both panels, only lane 1, medium 
from cells infected with the recombinant virus 
vTF7-3 and transfected with the plasmid contain- 
ing the POMC cDNA sequence in the correct 
or ientat ion (pKA2) showed a POMC band im- 
munosta ined with both ACTH and ~'-endorphin 
antisera (fig. 1, arrow). This band was not present 
in cells transfected with a plasmid containing the 
POMC cDNA sequence in the wrong orientation 
(pKAS, lane 2), in cells infected with wild type vac- 
cinia virus and transfected with either pKA2 or 
pKA5 (lanes 3 and 4, respectively), or in un- 
transfected cells (lane 5). Analysis of the size of 
a 
Anti-/J-END 
1 2 3 4 5 
b 
Anti-ACTH 
1 2 3 4 5 
POMC'-'~ 
~43K m 
- -25K~ 
~18K~ 
- -15K~ 
~6K 
"'--POMC 
Fig.l. (a) SDS-PAGE and immunoblots (Western blots) of medium from CV-1 cells immunostained with ~-endorphin (DP3) 
antiserum. (b) SDS-PAGE and immunoblots of medium from CV-I cells immunostained with ACTH (DP4) antiserum. Lanes 1-5 
in each panel represent medium from CV-1 cells infected with vTF7-3 recombinant vaccinia virus and tran fected with pKA2 (lane 
1) or pKA5 (lane 2); or infected with wild type vaccinia virus and transfected with pKA2 (lane 3) or pKA5 (lane 4); or untransfected 
CV-I cells (lane 5). Molecular mass markers (K = 103) are indicated and the arrows show the POMC band immunostained with ~'- 
endorphin and ACTH antisera in lane 1 of panels a nd b, respectively. 
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Fig.2. (A) SDS-PAGE of anti-ACTH (O---O) and anti- 
endorphin (+---a) immunoprecipitated [‘H]Arg-labeled 
POMC eluted from an acid gel (see section 2). A diagrammatic 
representation of mouse POMC showing the paired basic 
residues (K = Lys, R = Arg) and glycosylation sites (a) is shown 
above panel A. (B) SDS-PAGE of anti-ACTH (O---O) and 
anti-endorphin (M) immunoprecipitated [3H]proteins 
generated after incubation of [‘H]Arg-labeled, purified POMC 
(see A) with bovine intermediate lobe POMC-converting 
enzyme for 5 h at 37°C in 0.1 M sodium citrate buffer, pH 4.0. 
this POMC band indicated a molecular mass rang- 
ing from 30 to 36 kDa. Similar results were obtain- 
ed when CV-1 cells were transfected with pKA2 in 
the presence of [3H]Arg. A radiolabeled POMC 
peak (33 kDa) which was immunoprecipitated with 
ACTH and ,&endorphin antibodies was detected 
(data not shown). However, in both the Western 
blot (fig.1) and radiolabeled experiments, a large 
molecular mass band (243 kDa) was also present. 
In addition, very small amounts of [3H]Arg- 
labeled, ACTH-related degradation products were 
detectable. Purification of the anti-ACTH im- 
munoprecipitated [3H]Arg-labeled prohormone by 
acid gel electrophoresis virtually eliminated all of 
the contaminating peaks, yielding a relatively pure 
preparation of POMC suitable for use as substrate 
for processing enzymes (see fig.2A). 
Radioimmunoassay for ACTH using an an- 
tibody that recognizes intact POMC as well as pro- 
cessed products on an equimolar basis showed that 
this transient transfection system yielded l-2 pg 
immunoreactive ACTH/106 cells. This is 
equivalent to a minimum yield of 220 pmol 
ACTH, or 220 pmol POMC per lo6 cells (since 
there is 1 mol of ACTH per POMC molecule). 
Typically incorporation of [3H]Arg into POMC 
was 5 x lo5 cpm/106 cells. Thus, the specific ac- 
tivity of POMC produced was generally in the 
range of 0.1-0.2 x 104 cpm/pmol. 
3.2. Processing of CHJArg-POMC by POMC- 
converting enzyme 
Fig.2B shows the SDS gel profile of [3H]Arg- 
labeled products generated from expressed 
[3H]Arg-POMC by incubation with POMC- 
converting enzyme (PCE). Several forms of ACTH 
intermediates, 19-25 kDa, as well as &LPH and 
,&endorphin were observed. These forms represent 
products cleaved at paired basic residues of POMC 
(see fig.2) and their sizes correspond to those seen 
in the mouse intermediate lobe in situ [ 151. Incuba- 
tion of [3H]Arg-POMC in the absence of enzyme 
did not yield any processed products (data not 
shown). 
4. DISCUSSION 
In this study, we have applied a previously 
described method using a recombinant vaccinia 
virus containing the sequence for a T7 RNA 
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polymerase and a plasmid carrying the T7 RNA 
polymerase promoter and terminator to produce 
microgram quantities of the prohormone, 
POMC/106 CV-1 cells. Moreover, we have 
demonstrated that [3H]amino acid-labeled POMC 
produced in this manner is suitable for use as a 
substrate for processing enzymes. However, it has 
to be noted that the specific activity of radiola- 
beled POMC from CV-1 cells was at least lo-fold 
lower than that synthesized in mouse intermediate 
lobe after a 30-60 min pulse-labeling (unpublished 
data). Hence, more enzyme is required to cleave 
sufficient prohormone to yield detectable 
products. 
Another consideration of the method is the post- 
translational modification state of POMC pro- 
duced by CV-1 cells. The broad (30-36 kDa) 
POMC band seen on the gels suggests that hetero- 
geneous glycosylated forms of POMC may be pro- 
duced by the transfected CV-1 cells. Cell-free 
translated, non-glycosylated POMC has a mole- 
cular mass of 28.5 kDa [16]. Indeed, multiple 
glycosylated forms of POMC, 30-36 kDa, have 
been reported in mouse and rat pituitary [17-191. 
Also, consistent with this interpretation was the 
observation that cleavage of expressed POMC by 
PCE yielded different forms of ACTH inter- 
mediates which were similar in size to those 
glycosylated forms found in the mouse pituitary 
[ 15,181. Nevertheless, although the size of POMC 
expressed in CV-1 cells was similar to that found in 
mouse pituitary, it remains unknown if the car- 
bohydrate structure is identical to its endogenous 
counterpart. 
Vaccinia virus as an expression system has also 
been used by Thomas and co-workers [19,20] to 
produce pro-enkephalin and POMC. In their 
studies, a recombinant vaccinia virus containing 
the pro-enkephalin or POMC cDNA sequence was 
used to infect different cell lines including BSC-40, 
a green monkey kidney cell line. Their procedure 
yielded 22 pmol immunoreactive ACTH/106 
BSC40 cells [20] in the medium, which is one- 
tenth of that described in this study. Moreover, in 
our method, construction of a vaccinia recombi- 
nant virus containing POMC DNA was not re- 
quired. 
In conclusion, the demonstration that a vaccinia 
virus transient transfection system can be applied 
to a mammalian cell line to produce microgram 
quantities of intact, glycosylated POMC which can 
be cleaved by the bovine secretory vesicle 
prohormone-converting enzyme, paves the way for 
producing various genetically modified prohor- 
mone substrates for structure-function studies in 
the future. Such studies will further the understan- 
ding of the role prohormone conformation plays in 
determining the specificity of cleavage. 
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